Xeljanz
High-Dose Tofacitinib Cuts Colectomy Rates For Acute Severe UC
A regimen of three daily doses of tofacitinib (Xeljanz, Pfizer) slashed rates of colectomy by nearly 90% in ...
NOVEMBER 10, 2021
FDA Warns of Serious Risks, Including Death, With JAK Inhibitors
The FDA is requiring the addition of warnings about increased risks for cancer, serious cardiovascular events and ...
SEPTEMBER 2, 2021
FDA Warns of Possible Serious CV Events, Cancer Linked to Xeljanz
The FDA issued an alert concerning an increased risk for serious cardiovascular events and malignancies with the ...
FEBRUARY 6, 2021
Tofacitinib Data Shed Light on DVT/PE Rates, Reescalation Success in UC
In July 2019, the FDA added a boxed warning to the package insert of tofacitinib (Xeljanz, Pfizer), cautioning ...
SEPTEMBER 16, 2020
FDA Issues New Boxed Warning for Xeljanz, Xeljanz XR
Twice-daily 10-mg dose of tofacitinib linked to increased risk for blood clots and death.
JULY 29, 2019
Higher Dose of UC Drug Xeljanz Increased Clot Risk in RA Study
The FDA issued a safety announcement alerting health professionals and the public about an increased risk for ...
FEBRUARY 27, 2019
FDA Approves Xeljanz for UC
The FDA has approved tofacitinib (Xeljanz, Pfizer) for the treatment of patients with moderate to severe ulcerative ...
MAY 30, 2018